MX2021010061A - Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. - Google Patents

Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.

Info

Publication number
MX2021010061A
MX2021010061A MX2021010061A MX2021010061A MX2021010061A MX 2021010061 A MX2021010061 A MX 2021010061A MX 2021010061 A MX2021010061 A MX 2021010061A MX 2021010061 A MX2021010061 A MX 2021010061A MX 2021010061 A MX2021010061 A MX 2021010061A
Authority
MX
Mexico
Prior art keywords
treating
fusion proteins
extracellular domain
negative tumors
domain
Prior art date
Application number
MX2021010061A
Other languages
English (en)
Inventor
Barbara Sennino
Susannah D Barbee
Thomas Brennan
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2021010061A publication Critical patent/MX2021010061A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente descripción proporciona métodos para tratar tumores negativos para PD-L1, los métodos comprenden administrar proteínas de fusión que comprenden el dominio extracelular del conglomerado de diferenciación 80 (CD80) humano y el dominio de fragmentos cristalizables (Fc) de inmunoglobulina G 1 (IgG1) humana.
MX2021010061A 2019-02-22 2020-02-21 Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. MX2021010061A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809319P 2019-02-22 2019-02-22
US201962815249P 2019-03-07 2019-03-07
PCT/US2020/019135 WO2020172482A2 (en) 2019-02-22 2020-02-21 Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors

Publications (1)

Publication Number Publication Date
MX2021010061A true MX2021010061A (es) 2021-12-10

Family

ID=70057229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010061A MX2021010061A (es) 2019-02-22 2020-02-21 Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.

Country Status (10)

Country Link
US (1) US20220031806A1 (es)
EP (1) EP3927365A2 (es)
JP (1) JP2022521299A (es)
KR (1) KR20210130706A (es)
AU (1) AU2020224137A1 (es)
CA (1) CA3130752A1 (es)
MX (1) MX2021010061A (es)
SG (1) SG11202107966TA (es)
TW (1) TW202045544A (es)
WO (1) WO2020172482A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181300A1 (es) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
WO2021092084A1 (en) * 2019-11-04 2021-05-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
RU2715038C2 (ru) * 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
PE20181300A1 (es) * 2015-11-02 2018-08-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
SG11202107966TA (en) 2021-09-29
EP3927365A2 (en) 2021-12-29
US20220031806A1 (en) 2022-02-03
TW202045544A (zh) 2020-12-16
JP2022521299A (ja) 2022-04-06
AU2020224137A1 (en) 2021-10-14
CA3130752A1 (en) 2020-08-27
WO2020172482A2 (en) 2020-08-27
KR20210130706A (ko) 2021-11-01
WO2020172482A3 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
Peruzzi et al. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
MX2021014345A (es) Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.
MY194764A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
PH12020551026A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
MX2021004059A (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
WO2020072821A3 (en) Il-12 heterodimeric fc-fusion proteins
MX2021003435A (es) Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
MX2020012518A (es) Proteinas de fusion que comprenden progranulina.
WO2020231882A3 (en) Modified pluripotent cells
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
WO2019094595A3 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
MX2021005565A (es) Anticuerpos monoclonales antagonistas contra cumulo de diferenciacion 40 (cd40) y sus usos.
WO2019090215A3 (en) Dominant negative ligand chimeric antigen receptor systems
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
CR20220107A (es) Proteínas de fusión nkg2d y sus usos